Jun 02, 2026
Abivax (ABVX) Stock Plunges 32% Despite Breakthrough Trial Results
Abivax (ABVX) stock crashed 32% despite best-in-class Phase 3 results as rare cancer cases in trial participants triggered safety concerns and downgrades.
The post Abivax (ABVX) Stock Plunges 32% Despite Breakthrough Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 6 hours ago
SharpLink (SBET) Stock Climbs on Ethlabs Ethereum Research Initiative
- 6 hours ago
Oracle (ORCL) Stock Drops 4.61% as Baystate Health Partnership Expands
- 6 hours ago
Micron (MU) Stock Jumps Over 5% on Strategic Anthropic Partnership
- 8 hours ago
Alphabet (GOOGL) Stock Plunges 6% as AI Talent Exodus Continues to OpenAI and An...
- 8 hours ago
Accenture (ACN) Stock Plummets 25% in Historic Selloff Following Disappointing B...